Top

Published in:

01-08-2018 | Clinical trial

A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation

Authors: Joyce O’Shaughnessy, Angela DeMichele, Cynthia X. Ma, Paul Richards, Denise A. Yardley, Gail Shaw Wright, Kevin Kalinsky, Ronald Steis, Sami Diab, Gerard Kennealey, Ryan Geschwindt, Wei Jiang, Hope S. Rugo

Published in: Breast Cancer Research and Treatment | Issue 3/2018

Abstract

Purpose

The Janus-associated kinase (JAK)/signal transducer and activator of transcription pathway is a key regulator of inflammatory signaling, associated with tumorigenesis, cell survival, and progression. This randomized phase 2 trial evaluated the efficacy and safety of the addition of ruxolitinib, a JAK1/JAK2 inhibitor, to capecitabine in patients with HER2-negative advanced breast cancer and high systemic inflammation (modified Glasgow Prognostic Score [mGPS] ≥ 1).

Methods

Patients with ≤ 2 prior chemotherapy regimens for advanced or metastatic disease or hormone receptor-positive patients with disease progression on prior hormonal therapies were randomized 1:1 to 21-day cycles of ruxolitinib (n = 76) or placebo (n = 73) plus capecitabine. The primary endpoint was overall survival (OS).

Results

Baseline characteristics were well balanced between groups. For ruxolitinib plus capecitabine versus placebo plus capecitabine, median OS was 11.2 months versus 10.9 months (log-rank test P = 0.762); median progression-free survival (PFS) was 4.5 months versus 2.5 months (log-rank test P = 0.151); and overall response rate (ORR) was 28.9% versus 13.7% (Cochran–Mantel–Haenszel test P = 0.024), respectively. A more favorable change in health-related quality of life (HRQoL) was observed with ruxolitinib plus capecitabine versus placebo plus capecitabine. Both regimens were generally tolerable. A higher incidence of grade 3/4 anemia (25.4% vs 5.6%) and a lower incidence of grade 3/4 palmar–plantar erythrodysesthesia (1.4% vs 12.7%) occurred with ruxolitinib plus capecitabine versus placebo plus capecitabine.

Conclusions

The addition of ruxolitinib to capecitabine for patients with advanced breast cancer and high systemic inflammation was generally tolerable; ORR was numerically greater, a more favorable change in HRQoL was observed, but neither OS nor PFS was improved compared with placebo plus capecitabine.

Available only for authorised users

American Cancer Society (2015) Breast cancer. facts & figures 2015–2016. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2015-2016.pdf. Accessed 20 Dec 2017

Toss A, Venturelli M, Peterle C, Piacentini F, Cascinu S, Cortesi L (2017) Molecular biomarkers for prediction of targeted therapy response in metastatic breast cancer: trick or treat? Int J Mol Sci. https://doi.org/10.3390/ijms18010085 PubMedPubMedCentralCrossRef

Caffarel MM, Zaragoza R, Pensa S, Li J, Green AR, Watson CJ (2012) Constitutive activation of JAK2 in mammary epithelium elevates Stat5 signalling, promotes alveologenesis and resistance to cell death, and contributes to tumourigenesis. Cell Death Differ 19:511–522. https://doi.org/10.1038/cdd.2011.122 CrossRefPubMed

Quintás-Cardama A, Kantarjian H, Cortes J, Verstovsek S (2011) Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 10:127–140. https://doi.org/10.1038/nrd3264 CrossRefPubMed

Chang Q, Bournazou E, Sansone P et al (2013) The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia 15:848–862CrossRefPubMedPubMedCentral

Yu H, Kortylewski M, Pardoll D (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7:41–51. https://doi.org/10.1038/nri1995 CrossRefPubMed

Al Murri AM, Bartlett JM, Canney PA, Doughty JC, Wilson C, McMillan DC (2006) Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer 94:227–230. https://doi.org/10.1038/sj.bjc.6602922 CrossRefPubMed

Dethlefsen C, Højfeldt G, Hojman P (2013) The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat 138:657–664. https://doi.org/10.1007/s10549-013-2488-z CrossRefPubMed

McMillan DC (2013) The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev 39:534–540. https://doi.org/10.1016/j.ctrv.2012.08.003 CrossRefPubMed

10.

Jhaveri K, Teplinsky E, Silvera D et al (2016) Hyperactivated mTOR and JAK2/STAT3 pathways: molecular drivers and potential therapeutic targets of inflammatory and invasive ductal breast cancers after neoadjuvant chemotherapy. Clin Breast Cancer 16(113–122):e111. https://doi.org/10.1016/j.clbc.2015.11.006 CrossRef

11.

Long KB, Tooker G, Tooker E, Luque SL, Lee JW, Pan X, Beatty GL (2017) IL6 receptor blockade enhances chemotherapy efficacy in pancreatic ductal adenocarcinoma. Mol Cancer Ther 16:1898–1908. https://doi.org/10.1158/1535-7163.MCT-16-0899 CrossRefPubMedPubMedCentral

12.

Quintás-Cardama A, Vaddi K, Liu P et al (2010) Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115:3109–3117. https://doi.org/10.1182/blood-2009-04-214957 CrossRefPubMedPubMedCentral

13.

JAKAFI^® (2017) (ruxolitinib) tablets [package insert]. Incyte Corporation, Wilmington, DE, 2017. www.jakafi.com/pdf/prescribing-information.pdf. Accessed 20 Dec 2017

14.

JAKAVI^® (2017) (ruxolitinib) tablets [summary of product characteristics]. Novartis Europharm Limited, Camberley, 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002464/WC500133223.pdf. Accessed 20 Dec 2017

15.

XELODA^® (2017) (capecitabine) tablets [package insert]. Genentech, South San Francisco, 2017. https://www.gene.com/download/pdf/xeloda_prescribing.pdf. Accessed 20 Dec 2017

16.

Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, Osterwalder B (2001) Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92:1759–1768CrossRefPubMed

17.

Blum JL, Jones SE, Buzdar AU et al (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485–493. https://doi.org/10.1200/JCO.1999.17.2.485 CrossRefPubMed

18.

Hurwitz HI, Uppal N, Wagner SA et al (2015) Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J Clin Oncol 33:4039–4047. https://doi.org/10.1200/JCO.2015.61.4578 CrossRefPubMedPubMedCentral

19.

Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795. https://doi.org/10.1200/JCO.2009.25.6529 CrossRefPubMedPubMedCentral

20.

Wolff AC, Hammond ME, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013. https://doi.org/10.1200/JCO.2013.50.9984 CrossRefPubMed

21.

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026 CrossRefPubMed

22.

Guidance for Industry (2007) Clinical trial endpoints for the approval of cancer drugs and biologics. Food and Drug Administration (FDA). http://www.fda.gov/downloads/Drugs/…/Guidances/ucm071590.pdf. Accessed 15 Feb 2018

23.

Marotta LL, Almendro V, Marusyk A et al (2011) The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell–like breast cancer cells in human tumors. J Clin Invest 121:2723–2735. https://doi.org/10.1172/JCI44745 CrossRefPubMedPubMedCentral

24.

Al Murri AM, Wilson C, Lannigan A, Doughty JC, Angerson WJ, McArdle CS, McMillan DC (2007) Evaluation of the relationship between the systemic inflammatory response and cancer-specific survival in patients with primary operable breast cancer. Br J Cancer 96:891–895. https://doi.org/10.1038/sj.bjc.6603682 CrossRefPubMedPubMedCentral

25.

Pierce BL, Ballard-Barbash R, Bernstein L et al (2009) Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 27:3437–3444. https://doi.org/10.1200/JCO.2008.18.9068 CrossRefPubMedPubMedCentral

26.

Wen J, Ye F, Huang X, Li S, Yang L, Xiao X, Xie X (2015) Prognostic significance of preoperative circulating monocyte count in patients with breast cancer: based on a large cohort study. Medicine 94:e2266. https://doi.org/10.1097/MD.0000000000002266 CrossRefPubMedPubMedCentral

27.

Wang D, Duan L, Tu Z et al (2016) The Glasgow Prognostic Score predicts response to chemotherapy in patients with metastatic breast cancer. Chemotherapy 61:217–222. https://doi.org/10.1159/000443367 CrossRefPubMed

28.

Majello B, Arcone R, Toniatti C, Ciliberto G (1990) Constitutive and IL-6-induced nuclear factors that interact with the human C-reactive protein promoter. EMBO J 9:457–465PubMedPubMedCentralCrossRef

29.

Harrison C, Kiladjian JJ, Al-Ali HK et al (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366:787–798. https://doi.org/10.1056/NEJMoa1110556 CrossRefPubMed

30.

Verstovsek S, Mesa RA, Gotlib J et al (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799–807. https://doi.org/10.1056/NEJMoa1110557 CrossRefPubMedPubMedCentral

31.

Harrison CN, Mesa RA, Kiladjian JJ et al (2013) Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. Br J Haematol 162:229–239. https://doi.org/10.1111/bjh.12375 CrossRefPubMed

32.

Mesa R, Verstovsek S, Kiladjian JJ et al (2016) Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. Eur J Haematol 97:192–200. https://doi.org/10.1111/ejh.12707 CrossRefPubMed

33.

Eton DT, Cella D, Yost KJ et al (2004) A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol 57:898–910. https://doi.org/10.1016/j.jclinepi.2004.01.012 CrossRefPubMed

34.

Twelves C, Cortés J, O’Shaughnessy J et al (2017) Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician’s choice: results from the randomised phase III BEACON trial. Eur J Cancer 76:205–215. https://doi.org/10.1016/j.ejca.2017.02.011 CrossRefPubMed

35.

Mesa RA, Cortes J (2013) Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. J Hematol Oncol 6:79. https://doi.org/10.1186/1756-8722-6-79 CrossRefPubMedPubMedCentral

36.

Santos FP, Verstovsek S (2014) Efficacy of ruxolitinib for myelofibrosis. Expert Opin Pharmacother 15:1465–1473. https://doi.org/10.1517/14656566.2014.923404 CrossRefPubMedPubMedCentral

Title: A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation
Authors: Joyce O’Shaughnessy
Angela DeMichele
Cynthia X. Ma
Paul Richards
Denise A. Yardley
Gail Shaw Wright
Kevin Kalinsky
Ronald Steis
Sami Diab
Gerard Kennealey
Ryan Geschwindt
Wei Jiang
Hope S. Rugo
Publication date: 01-08-2018
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-4770-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2018

Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer

Physician peer group characteristics and timeliness of breast cancer surgery

Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan

Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system

Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy

Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer